Compare Organon & Co. Common Stock (OGN) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs RLX Technology Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while RLX Technology Inc trades at $1.7 (market cap $2.09B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and RLX Technology Inc pays the higher dividend (5.85%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and RLX Technology Inc for 36 Days on average.
| OGN | RLX | |
|---|---|---|
Market Cap | $3.61B | $2.09B |
Volume | 1,808,049 | 2,906,236 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $2.57 |
52-Week Low | $5.70 | $1.68 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $11.03B | $817.70M |
Dividend Yield | 0.58% | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
RLX Technology trades at $1.71, down 0.58% with bearish technical signals. The stock recently hit 52-week lows despite solid fundamentals including $3.62B revenue and 21.87% net margin. Recent earnings missed expectations but international expansion shows growth potential. Technical indicators show selling pressure with bearish moving averages.
RLX presents a value opportunity with discounted valuation (P/E 15.34, P/B 0.9) but faces execution risks. The bearish technical trend and earnings misses offset strong cash flow and international growth. Investors should weigh the discounted valuation against recent price weakness and margin compression concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
